Package Leaflet: Information for the User
Sugammadex Orion 100 mg/ml Solution for Injection EFG
Read all of this leaflet carefully before you are given this medicine because it contains important information for you.
Contents of the Package Leaflet
What is Sugammadex Orion
Sugammadex Orion contains the active substance sugammadex. Sugammadex Orion is considered a Selective Relaxant Binding Agentas it only works with specific muscle relaxants, namely rocuronium bromide or vecuronium bromide.
What Sugammadex Orion is used for
If you need to undergo surgery, your muscles must be completely relaxed, making it easier for the surgeon to perform the operation. For this, you will be given medications during general anesthesia to relax your muscles. These are called muscle relaxants, such as rocuronium bromide and vecuronium bromide. Since these medications also block the respiratory muscles, you will need help breathing (artificial respiration) during and after surgery until you can breathe on your own again.
Sugammadex is used to speed up the recovery of your muscles after surgery so that you can breathe on your own again sooner. It does this by binding to rocuronium bromide or vecuronium bromide in your body. It can be used in adults when rocuronium bromide or vecuronium bromide is used.
It can also be used in newborns, infants, children, and adolescents (from birth to 17 years) when rocuronium bromide is used.
You must not be given Sugammadex Orion
Tell your anesthesiologist if this applies to you.
Warnings and precautions
Consult your anesthesiologist before starting treatment with Sugammadex
Other medicines and Sugammadex Orion
Tell your anesthesiologist if you are taking, have recently taken, or might take any other medicines.
Sugammadex may affect other medicines or be affected by them.
Some medicines reduce the effect of Sugammadex Orion
It is especially important that you inform your anesthesiologist if you have recently taken:
Sugammadex Orion may affect hormonal contraceptives
→ If you are taking the Pillon the same day that you are given Sugammadex, follow the instructions for missing a pill in the pill leaflet.
→ If you are using otherhormonal contraceptives (e.g., a vaginal ring, an implant, or an IUD-h), you should use a non-hormonal contraceptive method (such as a condom) for the next 7 days and follow the recommendations in the leaflet.
Effects on blood tests
In general, Sugammadex does not affect laboratory tests. However, it may affect the results of a blood test when progesterone levels are measured. Consult your doctor if your progesterone levels need to be analyzed on the same day you receive Sugammadex.
Pregnancy and breastfeeding
Tell your anesthesiologist if you are pregnant or think you may be pregnant or if you are breastfeeding.
Sugammadex may still be given to you, but it needs to be discussed beforehand. It is not known whether sugammadex passes into breast milk. Your anesthesiologist will help you decide whether to interrupt breastfeeding or avoid treatment with sugammadex, considering the benefit of breastfeeding to the baby and the benefit of Sugammadex to the mother.
Driving and using machines
Sugammadex has no known influence on your ability to drive and use machines.
Sugammadex Orion contains sodium
This medicine contains up to 9.5 mg of sodium (the main component of cooking/table salt) per ml. This is equivalent to 0.5% of the maximum recommended daily intake of sodium for an adult.
Sugammadex will be administered to you by your anesthesiologist or under their supervision.
Dose
Your anesthesiologist will calculate the dose of sugammadex you need based on:
The usual dose is 2 to 4 mg per kg of body weight for patients of any age. A dose of 16 mg/kg may be used in adults if urgent recovery from muscle relaxation is needed.
How Sugammadex Orion is administered
Sugammadex will be administered to you by your anesthesiologist. It is injected once into a vein.
If you are given too much Sugammadex Orion
Since your anesthesiologist will be carefully monitoring the situation, it is unlikely that you will be given too much sugammadex. But even if this happens, it is unlikely to cause any problems.
If you have any further questions on the use of this medicine, ask your anesthesiologist or another doctor.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
If these side effects occur while you are under anesthesia, your anesthesiologist will detect and treat them.
Common (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people):
Rare (cannot be estimated from the available data):
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist, even if it is not listed in this leaflet. You can also report side effects directly through the Spanish Medicines Agency's website: www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Storage will be the responsibility of healthcare professionals.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and on the label after EXP. The expiry date is the last day of the month stated.
This medicine does not require any special storage conditions.
Do not freeze.
Keep the vial in the outer packaging to protect it from light.
After opening and dilution, store at 2-8 °C and use within 24 hours.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition of Sugammadex Orion
Each ml of solution for injection contains sugammadex sodium equivalent to 100 mg of sugammadex.
Each 2 ml vial contains sugammadex sodium equivalent to 200 mg of sugammadex.
Each 5 ml vial contains sugammadex sodium equivalent to 500 mg of sugammadex.
Appearance and packaging
Clear, colorless to slightly yellowish solution, free from visible particles.
It is available in:
1 vial of 2 ml, 10 vials of 2 ml
1 vial of 5 ml, 10 vials of 5 ml.
Not all pack sizes may be marketed.
Marketing authorization holder and manufacturer
Orion Corporation
Orionintie 1
FI-02200 Espoo
Finland
Orion Corporation
Orion Pharma
Orionintie 1
FI-02200 Espoo
Finland
Orion Corporation
Orion Pharma
Joensuunkatu 7
FI-24100 Salo
Finland
You can request more information about this medicine from the local representative of the marketing authorization holder:
Orion Pharma, S.L.
Avda. Alberto Alcocer 46B
28016 – Madrid
Spain
Phone: +349 159 9 86 01
Date of last revision of this leaflet:05/2025
Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/)